Buprenorphine in New York State: A Clinical Overview

Module number
Date presented
April 2, 2019 
CE Credit

On Tuesday, April 2nd, Dr. Kelly Ramsey of HRHCare presented on: “Buprenorphine in New York State: A Clinical Overview”

Lecture Objectives:
1. Identify how buprenorphine fits into a harm reduction framework.
2. Review federal and state requirements for prescribing buprenorphine.
3. Discuss perceived challenges in buprenorphine implementation and strategies to overcome them.

Presenter Bio:
Dr. Kelly S. Ramsey is an internal medicine physician with a focused practice on HIV, HCV, and substance use disorder (including Medication Assisted Treatment for opioid use disorder). She is the Medical Director of Substance Use Disorders at HRHCare, a network of community health centers, where she’s been since 2011. Prior to 2011, Dr. Ramsey served as the Medical Director of the Wellness Center at Port Morris in the Division of Substance Abuse at the Albert Einstein College of Medicine and as an attending Physician in Internal Medicine at Montefiore Medical Center. Dr. Ramsey provides expert advice to the New York State Department of Health AIDS Institute by serving on numerous committees, including the Quality of Care Advisory Committee (QAC), Substance Use Guidelines Committee for the HIV Clinical Practice Guidelines, Drug User Anti-Stigma Campaign, and the Office of Drug User Health’s NYS Buprenorphine Advisory Group.

Access the slides here